A biotechnology startup operating out of New York City is openly challenging one of the most firmly established ethical and legal boundaries in modern medicine: the prohibition on creating genetically modified human babies. The company, Origin Genomics, has begun making the case that the potential benefits of correcting disease-causing genes in human embryos may now outweigh the risks that prompted a global ban on the practice.
Cathy Tie, the founder and chief executive of Origin Genomics, recently gave NPR an exclusive tour of the company's laboratory facilities. She asked that the precise address not be disclosed, citing security concerns — a precaution that underscores how contentious the field of heritable human gene editing remains.
Tie walked reporters through the lab while wearing a white coat embroidered with her name and the company's logo. Inside, she pointed out equipment that forms the backbone of the startup's research, including a gray metal cryogenic tank resembling an oversized thermos that holds liquid nitrogen.
According to Tie, that tank is where the company stores human embryos. Opening the lid released curls of white vapor, and she carefully withdrew a long metal rod holding frosted glass tubes. She explained that the device held four tubes, each capable of holding as many as ten embryos.
Those embryos were not created for research purposes. They were donated by couples whose families have been affected for generations by severe, potentially life-threatening inherited disorders. One husband and wife who contributed embryos later spoke with NPR about their hope of one day having healthy children through the use of gene editing.
The scientific work at Origin Genomics centers on extracting stem cells from donated embryos in order to test the company's gene-repair technology. The goal is to demonstrate that editing disease-causing mutations in embryos can be done reliably and safely enough to justify moving the technique toward clinical use.
That ambition places Origin Genomics in direct conflict with a widely observed international consensus. Editing the genes of human embryos in ways that would be passed on to future generations is illegal in most countries, and the practice has been condemned by leading scientific bodies since the emergence of CRISPR technology made precise genetic modification far easier.
The current legal landscape traces back to a series of scientific and ethical reckonings. In 2018, a Chinese researcher stunned the world by announcing the birth of twin girls whose embryos he had edited, a case that drew near-universal condemnation and resulted in a prison sentence for the scientist involved. That episode hardened opposition to heritable editing and prompted calls for stronger enforcement of existing restrictions.
Despite that history, Origin Genomics argues that the conversation should not be permanently closed. The company's leadership contends that the technology has advanced considerably and that the suffering caused by devastating genetic diseases deserves a fresh look at whether carefully regulated editing could be permitted.
Supporters of the research point out that many families carry mutations for conditions such as Huntington's disease, cystic fibrosis, and certain forms of inherited cancer that can be passed to children with devastating consequences. For those families, embryo screening during in vitro fertilization can sometimes help, but it cannot eliminate a mutation when every embryo carries it or when the condition is caused by a dominant gene.
Critics, however, warn that the risks remain profound and poorly understood. Editing embryos can introduce unintended changes to the genome, a phenomenon known as off-target effects, and the full consequences of such alterations may not appear until generations later. Opponents also caution that permitting heritable editing would open the door to non-medical enhancements, raising the specter of designer babies available only to those who can afford them.
The ethical questions extend beyond safety. Disability advocates and bioethicists have argued that framing genetic conditions solely as defects to be eliminated can stigmatize people living with those conditions. Others question whether it is appropriate to modify the genetic inheritance of a person who cannot consent to the change.
Regulatory oversight in the United States is fragmented. While federal law prohibits the use of government funds for research involving the modification of human embryos, and the Food and Drug Administration has signaled that it would not approve such trials, there is no single statute that criminalizes the practice nationwide in the way some other countries have done.
That patchwork approach leaves room for privately funded ventures like Origin Genomics to operate in a gray area, conducting laboratory research that stops short of transferring edited embryos into a womb. Tie's company appears to be positioning itself at that boundary, testing its technology on donated embryos while making a public argument for reconsideration of the rules.
How regulators, scientists, and the public respond could shape the next chapter of human genetic research. For the families who donated embryos to Origin Genomics, the stakes are deeply personal, tied to the possibility of ending a cycle of inherited illness. For the broader society, the question is whether the promise of preventing disease justifies crossing a line that the scientific community drew only a few years ago.
For now, Origin Genomics is proceeding cautiously, keeping its location confidential and framing its work as a first step in a longer effort to prove that its technology is safe. Whether that effort persuades policymakers to revisit the ban — or provokes a backlash that reinforces it — remains an open question.
(0)